Levetiracetam-d6 is a deuterated derivative of Levetiracetam, a stable isotope-labeled compound containing six deuterium atoms. Levetiracetam is an antiepileptic drug that inhibits epileptic seizures by binding to synaptic vesicle protein 2A (SV2A) and modulating neurotransmitter release[1,2]. Levetiracetam-d6 is commonly used as an internal standard in LC-MS/MS for the quantitative analysis of Levetiracetam concentrations in biological samples (e.g., plasma, urine) and for pharmacokinetic studies[3,4,5].
Reference:
[1] LYSONG-WILLIAMSON K A. Levetiracetam: a review of its use in epilepsy[J]. Drugs, 2011, 71(4): 489-514.
[2] ABOU-KHALIL B. Levetiracetam in the treatment of epilepsy[J]. Neuropsychiatric Disease and Treatment, 2008, 4(3): 507-523.
[3] NIKOLAOU P, PAPOUTSIS I, DONA A, et al. Development and validation of a GC/MS method for the simultaneous determination of levetiracetam and lamotrigine in whole blood[J]. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102: 25-32.
[4] BOUDRIau S, HANZEL C, MASSICOTTE J, et al. Randomized comparative bioavailability of a novel three-dimensional printed fast-melt formulation of levetiracetam following the administration of a single 1000-mg dose to healthy human volunteers under fasting and fed conditions[J]. Drugs in R&D, 2016, 16(2): 229-238.
[5] SIME F B, ROBERTS J A, JEFFREE R L, et al. Population pharmacokinetics of levetiracetam in patients with traumatic brain injury and subarachnoid hemorrhage exhibiting augmented renal clearance[J]. Clinical Pharmacokinetics, 2021, 60(5): 655-664.
Levetiracetam-d6是Levetiracetam的氘代衍生物，是一种含有6个氘原子的稳定同位素标记化合物。Levetiracetam是一种抗癫痫药物，可通过与突触囊泡蛋白2A（SV2A）结合调节神经递质的释放，从而抑制癫痫的发作[1,2]。Levetiracetam-d6通常在LC-MS/MS中作为内标物，用于生物样本（如血浆、尿液）中Levetiracetam药物浓度的定量分析和药代动力学研究[3,4,5]。